Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

Clinical trial NCT04734379 · UNKNOWN

Trial details

NCT number: NCT04734379
Sponsor: Woolsey Pharmaceuticals
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Progressive Supranuclear Palsy Corticobasal Syndrome

Start date: 2021-01-22
Primary completion: 2022-11-30
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.